Horizon Discovery Group PLC (LON:HZD)

Horizon Discovery Group PLC (LON:HZD)

Share Price
157.80 p
7.8 (5.20 %)
Market Cap
£237.39 m
Proactive Investors - Run By Investors For Investors

Horizon Discovery Group PLC RNS Release

Result of AGM

RNS Number : 6477C
Horizon Discovery Group plc
18 June 2019


Horizon Discovery Group plc


Result of AGM


Cambridge, UK, 18 June 2019: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or "the Company"), a global leader in the application of gene editing and gene modulation technologies, announces that at its Annual General Meeting held today at 12.00 p.m. at the Company's offices, all resolutions were duly passed.




For further information from Horizon Discovery Group plc, please contact:

Horizon Discovery Group plc

Terry Pizzie, Chief Executive Officer

Jayesh Pankhania, Chief Financial Officer

Jon Davies, Head of Investor Relations

Tel: +44 (0) 1223 655 580


Numis Securities Limited (Broker and NOMAD)

James Black / Freddie Barnfield / Duncan Monteith

Tel: +44 (0) 207 260 1000


Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Matthew Neal / Melissa Gardiner

Tel: +44 (0) 20 3709 5700

Email: [email protected]



About Horizon Discovery Group plc www.horizondiscovery.com


Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation tools and their use. We have more than 10 years' experience of building cell models and our unmatched toolset and expertise enable our customers to answer key questions across research, drug discovery, drug development and diagnostics.


Horizon's platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell-lines. Our customers include many of the world's leading academic institutes and global pharmaceutical companies. Our expertise and insights into the challenges that they face, is driving us to create innovative products and services that not only differentiate our business, but also help our customers to achieve deeper understanding of biological systems, thereby fuelling the development of the next wave of precision medicine.


Horizon is headquartered in Cambridge, UK with offices in USA and Japan.  The Group is listed on the London Stock Exchange's AIM market under the ticker HZD.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Horizon Discovery Group PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use